novo nordisk oral semaglutide Efficacy and safety of by subgroups of patient characteristics in the PIONEER phase 3 programme US FDA accepts Novo Nordisk's

Researchers in China synthesized an optical-magnetic multimodal probe targeting TfR1, a ferroptosis-specific molecular marker, and employed molecular imaging technology to achieve dynamic visualization and monitoring of tanshinone IIA efficacy in treating myocardial ischemia/reperfusion injury and elucidating ferroptosis pathway regulatory mechanisms

5-12 The most common patient-reported adverse effects (AEs) associated with GLP-1 RAs and dual GIP/GLP-1 RAs are gastrointestinal (GI) in nature and may include abdominal pain, constipation, diarrhea, nausea, and vomiting

a high protein, low carbohydrate diet), portion control, and time-restricted eating easier

full Phase 3 data are required before regulatory submission or NHS use